dromlakhani Pretreat with bisphosphonate before surgery for pagetic bone neoplasm
STEP 1 — Gather Information
Confirm Paget’s disease diagnosis (plain radiographs, bone scan), assess for neoplastic lesion (MRI/CT, biopsy if indicated), obtain orthopedic oncology evaluation, check serum ALP, bone turnover markers, renal function, calcium, vitamin D, and coagulation status. Document findings and proceed to risk assessment.
STEP 2 — Rule In / Rule Out
Is there suspicion of osteosarcoma or giant cell tumor arising in pagetic bone? If yes, proceed to surgical planning; if no, manage Paget’s disease per standard care and do not pursue neoplasm‑specific pretreatment.
STEP 3 — Classify or Stratify
If the orthopedic surgeon plans operative intervention (biopsy, resection, or stabilization), classify as needing preoperative bisphosphonate pretreatment; if surgery is not planned, no pretreatment is required for bleeding risk reduction.
STEP 4 — Decide
Administer a potent bisphosphonate (e.g., intravenous zoledronate 5 mg) 1–2 months preoperatively after correcting vitamin D deficiency and ensuring euglycemia and adequate renal function; if bisphosphonate is contraindicated, consider delaying surgery or using alternative hemostatic measures.
Clinical Guardrails / Mimics / Pitfalls
Do not give bisphosphonate in severe renal impairment (eGFR <35 mL/min), untreated hypocalcemia, or vitamin D deficiency; avoid high‑dose etidronate preoperatively due to fracture risk; do not delay definitive oncologic surgery unnecessarily; monitor for acute phase reaction, hypocalcemia, and atypical femoral fracture with long‑term use.
Concrete Clinical Example
A 68‑year‑old with known Paget’s disease of the femur presents with worsening pain; MRI shows a lytic lesion suggestive of osteosarcoma. Orthopedic oncology confirms suspicion and plans wide resection. Pretreatment with IV zoledronate 5 mg is given 6 weeks pre‑operatively after vitamin D supplementation and confirmation of normal renal function. Surgery proceeds with markedly reduced intraoperative bleeding and no transfusion requirement.
Source: Paget’s Disease of Bone: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI: 10.1210/jc.2014-2910